Previous Article | Next Article 
Journal of Virology, May 1999, p. 3835-3842, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Identification of a Cell Surface Protein from
Crandell Feline Kidney Cells That Specifically Binds Aleutian Mink
Disease Parvovirus
James M.
Fox* and
Marshall E.
Bloom
Laboratory of Persistent Viral Diseases,
Rocky Mountain Laboratories, National Institute of Allergy and
Infectious Diseases, National Institutes of Health, Hamilton, Montana
59840
Received 25 August 1998/Accepted 19 January 1999
 |
ABSTRACT |
Aleutian mink disease parvovirus (ADV) is the etiological agent of
Aleutian disease of mink. The acute disease caused by ADV consists of
permissive infection of alveolar type II cells that results in
interstitial pneumonitis. The permissive infection is experimentally
modeled in vitro by infecting Crandell feline kidney (CrFK) cells with
a tissue culture-adapted isolate of ADV, ADV-G. ADV-G VP2 empty virions
expressed in a recombinant baculovirus system were analyzed for the
ability to bind to the surface of CrFK cells. Radiolabeled VP2 virions
bound CrFK cells specifically, while they did not bind either Mus
dunni or Spodoptera frugiperda cells, cells which are
resistant to ADV infection. The binding to CrFK cells was competitively
inhibited by VP2 virions but not by virions of cowpea chlorotic mottle
virus (CCMV), another unenveloped virus similar in size to ADV.
Furthermore, preincubation of CrFK cells with the VP2 virions blocked
infection by ADV-G. The VP2 virions were used in a virus overlay
protein binding assay to identify a single protein of approximately 67 kDa, named ABP (for ADV binding protein), that demonstrates specific
binding of VP2 virions. Exogenously added VP2 virions were able to
competitively inhibit the binding of labeled VP2 virions to ABP, while
CCMV virions had no effect. Polyclonal antibodies raised against ABP reacted with ABP on the outer surface of CrFK cells and blocked infection of CrFK cells by ADV-G. In addition, VP2 virion attachment to
CrFK cells was blocked when the VP2 virions were preincubated with
partially purified ABP. Taken together, these results indicate that ABP
is a cellular receptor for ADV.
 |
INTRODUCTION |
Aleutian mink disease
parvovirus (ADV) causes both chronic and acute disease in mink.
The chronic disease, termed Aleutian disease, is associated with a
persistent infection of adult mink and is characterized by viral
persistence, hypergammaglobulinemia, plasmacytosis, increased
CD8+ lymphocytes, and immune complex disorder (reviewed in
reference 12). Macrophages have been identified as
sites of restricted virus replication, and infection of these cells is
thought to lead to the immune disturbance (3, 36, 37). ADV
gains entry into macrophages by Fc-mediated uptake of antibody-virus
complexes, a process called antibody-dependent enhancement of infection
(22, 28, 31).
The acute disease, which occurs in newborn mink, is a fulminant, fatal
interstitial pneumonitis. A permissive ADV infection occurs in
alveolar type II cells, which leads to disturbances in surfactant
secretion within the lung (12). The mechanism by which ADV
attaches to and gains entry into these cells is not understood. Unlike
macrophages, type II cells are not phagocytic and do not bear Fc
receptors. The permissive infection is mimicked by infecting Crandell
feline kidney (CrFK) cells with a tissue culture isolate of ADV named
ADV-G (9, 13, 41). It is believed that ADV entry into both
type II cells and CrFK cells is receptor mediated. ADV is capable of
infecting many different mustelid hosts, including mink, ferrets,
weasels, fishers, marten, skunks, otters, raccoons, and foxes (5,
24, 27). The broad host range exhibited by ADV suggests that it
may utilize a cellular receptor that is widely distributed among the
different mustelids.
The initial event in a virus infection is the attachment of viruses to
the surface of the cell. Virus attachment is usually dependent on a
specific virus receptor on the cell surface, and the presence of the
receptor can be a major factor in determining viral tissue tropism and
host range. A large variety of molecules have been identified as virus
receptors. Virus receptors range from ubiquitous cell surface moieties,
such as carbohydrates, to cell-specific membrane proteins with various
functions (8, 20, 38, 47). Attachment to the surface of
cells by some viruses requires only the presence of specific
carbohydrates, as in the case of adeno-associated virus
(44). Other viruses, such as echoviruses, utilize specific
glycoproteins as receptors, where both the protein and carbohydrate
moiety are necessary for receptor function (32). In
addition, some viruses (e.g., dengue virus) utilize receptors
consisting only of protein without a carbohydrate moiety
(42). Regardless of which molecule or combination of
molecules is utilized as the virus receptor, the net effect is the
same: virus entry into the cell to establish infection. Characterization of virus receptors can provide insight into the basis
of virus host range and disease pathogenesis. In addition, defining the
specific chemical interactions that occur between a virus and its
receptor may enable the design of chemical therapies that can perturb
this interaction and prevent virus infection.
ADV, as well as many of the parvoviruses, exhibits many advantages for
examining virus-receptor interactions. The parvoviruses are small,
unenveloped viruses with single-stranded, negative-sense DNA genomes of
about 5,000 nucleotides (10). The T=1 ADV virion is comprised of two virion structural proteins designated VP1 and VP2
(2). ADV virions are extremely stable and are virtually impossible to dissociate in vitro without using reagents that unfold or
hydrolyze the individual proteins. Capsid proteins from several
parvoviruses, including ADV, have been shown to self-assemble into
empty capsids when expressed in insect cells by using recombinant baculoviruses (16, 17, 26, 43, 49). The ADV VP2 empty virion
(baculovirus-expressed) structure has recently been solved to 22-Å
resolution, and studies to solve the structure at a higher resolution
are under way (33). The baculovirus-expressed VP2 virions
provide an efficient, relatively easy system to purify large quantities
of virions for use in structural and receptor studies.
The cellular receptor has been characterized for 2 of the 31 described
eukaryotic parvoviruses. The human parvovirus B19 uses the erythrocyte
P antigen, a glycosophingolipid, as its cellular receptor
(15). The parvovirus adeno-associated virus type 2 was
recently reported to employ membrane-associated heparan sulfate proteoglycans as cellular receptors (44). A
requirement for sialic acid has been demonstrated for
hemagglutination by canine parvovirus (CPV) and feline panleukopenia
virus and for infection by minute virus of mice (6, 7, 18, 25, 35,
46). However, their specific cellular receptors have not been identified.
Because ADV permissively infects alveolar type II cells as well as CrFK
cells, it is possible that these cells have similar receptors for ADV.
The low number of alveolar type II cells in the lung combined with the
lack of an efficient method for isolating these cells technically
hinders the ability to identify the ADV cellular receptor in type II
cells. However, the advantages of working with the CrFK-ADV system
permitted us to initiate experiments to isolate the CrFK cell receptor.
In this study we have identified a single protein, denoted ADV binding
protein (ABP), with a molecular mass of 67 kDa that specifically binds
ADV-G VP2 virions.
 |
MATERIALS AND METHODS |
Viruses, cells, and plasmids.
The ADV-G strain used in this
study was derived from a molecularly cloned virus stock (XXI-Q-3-15)
(11). ADV-G was propagated in CrFK cells. CrFK and Mus
dunni cells were cultured at 37°C in Dulbecco's modified Eagle
medium (DMEM) supplemented with 10% fetal calf serum (Gibco-BRL,
Gaithersburg, Md.). Spodoptera frugiperda (SF9) cells, used
for baculovirus expression, were cultured in Grace's insect medium
(Gibco-BRL) supplemented with 10% fetal calf serum (Gibco-BRL).
Baculovirus expression of VP2 empty virions and iodination.
The VP2 virions were expressed, as previously described, in a
recombinant baculovirus, Autographa californica nuclear
polyhedrosis virus, encoding the ADV VP2 protein (17). One
modification to the previous protocol included maintaining the SF9
cells as suspension cultures by using spinner flasks. The Grace's
insect medium was supplemented with 0.05% Pluronic Polyol F-68
(Gibco-BRL). The SF9 cells were infected at a multiplicity of infection
(MOI) of 1 and cultured for 5 days postinfection. VP2 virions were
purified by collecting the infected SF9 cells, resuspending them in
lysis buffer (0.05 M Tris-HCl [pH 8.0], 0.15 M NaCl, 0.2% Triton
X-100, protease inhibitor cocktail [Pefabloc, 1 µg/ml; pepstatin, 1 µg/ml; aprotinin, 1 µg/ml; leupeptin, 5 µg/ml]), and
freeze-thawing four times. The suspension was sonicated on ice for
three cycles of 15 s each, chloroform extracted, sonicated for two
cycles of 15 s each, and centrifuged for 30 min at 10,000 rpm in a
JA-14 rotor (Beckman, Piscataway, N.J.). The aqueous phase was
subjected to a second chloroform extraction. The VP2 virions were
further purified by making the suspension 10% with polyethylene glycol
8000, stirring overnight at 4°C, and collecting the precipitated
virions by centrifugation at 10,000 rpm for 15 min in a JA-14 rotor.
The virion pellet was resuspended in 1/10 volume (of that of original
lysis buffer suspension) of storage buffer (0.05 M Tris-HCl [pH 8.0],
0.05 M NaCl) with protease inhibitor cocktail, dialyzed against storage
buffer, and stored at 4°C.
VP2 virions were labeled with 125I by incubating 100 µg
of VP2 virions with 1 mCi of Na125I (Amersham, Arlington
Heights, Ill.) in the presence of IODO-BEADS (Pierce, Rockford, Ill.)
as specified by the manufacturer. The labeled virions were purified
from free Na125I by using D-Salt desalting columns (Pierce)
and stored in Tris-EDTA buffer containing 50 mM NaCl. The specific
activity of the labeled virions was determined by protein quantitation
and radioactivity quantitation with a gamma counter.
Virion-cell binding assay.
CrFK cells were plated (5 × 106 cells/well) in a 12-well tissue culture plate and
incubated overnight at 37°C. The plate was incubated for 2 h at
4°C to chill the cells. The cells were incubated at 4°C for 1 h with 100,000 cpm of radiolabeled ADV VP2 virions (50 µg) in DMEM,
washed four times with 0.5 ml of ice-cold DMEM, and then lysed with a
buffer containing 0.01 M phosphate-buffered saline (PBS) (pH 7.2), 0.15 M CaCl2, 1% Triton X-100, and 0.1% sodium dodecyl sulfate
(SDS). The radioactivity was quantitated with a gamma counter.
Competition assays were performed by preincubating the cells with 900 µg of unlabeled virions for 15 min at 4°C in DMEM, followed by
addition of 100,000 cpm of radiolabeled ADV VP2 virions (as
described above). In blocking experiments, 125I-ADV
VP2 empty virions (100,000 cpm) were preincubated for 15 min with
either 500 µg of total CrFK cell membrane proteins, 200 µg of
partially purified ABP (approximately 70% pure as estimated by
Coomassie blue staining of an SDS-polyacrylamide gel), or 500 µg of
SF9 cell membrane proteins and then added to the cells and processed as
described above. In each experiment the assays were performed in
triplicate, and the average values from the three assays along with the
standard errors are reported.
Virus overlay protein binding assay (VOPBA).
CrFK membrane
proteins were purified from confluent cultures in T-150 tissue culture
flasks by washing three times with buffer A (0.02 M sodium phosphate
[pH 8.0], 0.005 M EDTA, 0.002 M N-ethylmaleimide, protease
inhibitor cocktail) at room temperature and scraping the cells into 5 ml of buffer A. The suspended cells were collected by centrifugation at
1,500 rpm for 5 min in a Beckman J-6 swinging-bucket centrifuge.
Pellets were resuspended in 2.5 ml of buffer A containing 0.5%
deoxycholate and 1% Triton X-100, incubated on ice for 10 min, and
centrifuged at 3,000 rpm for 15 min in a Beckman J-6 swinging-bucket
centrifuge. The supernatant, containing the membrane proteins, was
collected, supplemented with protease inhibitor cocktail, and stored at
20°C.
For further analysis, the membrane proteins (50 to 100 µg) were
separated in a nonreducing SDS-8% polyacrylamide gel, transferred
to
a polyvinylidene difluoride membrane (Sigma, St. Louis, Mo.),
and
refolded by incubating the blot in refolding buffer (0.01
M HEPES [pH
7.4], 0.01 M MgCl
2, 0.05 M NaCl, 0.001 M dithiothreitol,
10% glycerol, protease inhibitor cocktail) for 12 h at 4°C. The
blot was blocked in PBS containing 5% nonfat dry milk for 5 h
at
4°C and then reacted with 100,000 cpm of
125I-ADV VP2
empty virions (50 µg) in hybridization buffer (DMEM
containing 10%
fetal calf serum and 0.25 M NaCl) for 5 h at room
temperature.
Finally, the blots were washed four times with hybridization
buffer and
exposed to film. Competition experiments were performed
by adding
unlabeled virions (amounts are indicated in the figure
legends) to the
hybridization buffer just prior to addition of
the iodinated ADV VP2
virions.
Production of polyclonal antibody to ABP.
Comparison of
VOPBA blots with a parallel Coomassie blue-stained gel identified a
single protein band with an approximate molecular mass of 67 kDa as the
ABP, which was excised from the gel. The protein was electroeluted by
using a protein elution apparatus from Bio-Rad (Hercules Calif.) and
quantified by rerunning on an SDS-polyacrylamide gel, staining, and
comparing the band intensity with those of known standards. To confirm
that the eluted protein was a single protein rather than multiple
proteins with similar electrophoretic mobilities, a two-dimensional gel
was run. The first dimension was near-equilibrium pH gel
electrophoresis with ampholines with a pH range of 3.5 to 9.5, and the
second dimension was SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Silver staining of the gel revealed a single protein. Rabbits were
injected subcutaneously with approximately 100 µg of purified ABP
emulsified in Freund complete adjuvant. At 3, 6, and 9 weeks postinoculation, the rabbits were boosted with 100 µg of purified ABP
emulsified in Freund incomplete adjuvant. At 12 weeks postinoculation, the rabbits were exsanguinated under anesthesia and sera were collected.
Western blotting.
Purified CrFK membrane proteins (500 ng)
were separated in a nonreducing SDS-10% polyacrylamide gel,
transferred to a Hybond-C extra-nitrocellulose membrane (Amersham), and
blocked for 2 h in PBS containing 15% nonfat dry milk. The blots
were probed with anti-ABP serum diluted in PBS-0.05% Tween 20 (PBST)
containing 15% nonfat dry milk at room temperature for 1 h,
washed three times with PBST, and probed with horseradish
peroxidase-conjugated goat anti-rabbit antibody (ICN, Aurora Ohio)
diluted 1:3,000 in PBST containing 15% nonfat dry milk for 30 min at
room temperature. The blots were washed four times in PBST with a final
wash in PBS, developed by using the ECL Western blotting system
(Amersham) according to the manufacturer's specifications, and exposed
to film.
Blocking of ADV infection with ABP polyclonal antibody.
CrFK
cells (105 cells/well) were seeded in four-well
Chamber-Slides (Nunc Inc., Naperville, Ill.) and incubated overnight at 37°C. The slides were incubated at 4°C for 2 h, at which time the medium was removed and the cells were flooded with 0.25 ml of
ice-cold DMEM containing various dilutions of anti-ABP polyclonal serum
or normal rabbit serum (collected as prebleeds from rabbits used to
raise anti-ABP antibodies). The cell-antibody suspension was incubated
for 30 min at 4°C, after which ADV-G was added at an MOI of 1 focus-forming unit/cell. Incubation was continued at 4°C for 30 min,
and the cultures were then washed four times with 1.0 ml of ice-cold
DMEM. The cells were flooded with 1.0 ml of DMEM and incubated at
32°C for 3 days. Infectivity was analyzed by immunofluorescence
microscopy as described below.
Immunofluorescence microscopy.
In experiments examining
ADV-G infectivity, a polyclonal antibody to the ADV nonstructural 1 protein (NS1) diluted 1:20 in PBST was utilized to stain infected
cultures of CrFK cells (39). The primary NS1 antibody was
incubated with the cells for 30 min at room temperature, followed by
washing. A secondary fluorescein isothiocyanate (FITC)-conjugated goat
antirabbit antibody, diluted 1:1,000 in PBST, was incubated with the
cells for 30 min, followed by several washes and viewing with a Nikon
Microphot-SA microscope. The number of infected cells was determined by
averaging the counts from 20 fields of view in areas of equal cell density.
In examining ABP reactivity with CrFK cells, cells
(10
5/well) were seeded in four-well Chamber-Slides and
incubated overnight
at 37°C. The medium was removed from the cells,
the slides were
briefly washed in PBS, and the cells were fixed by
incubation
in 3.7% formaldehyde diluted in PBS for 1 h at room
temperature.
Blocking was accomplished by addition of PBS containing
5% nonfat
dry milk, 4% bovine serum albumin fraction V, and 5%
bovine fetal
calf serum and incubation for 1 h at room
temperature. The blocking
buffer was removed by aspiration, and
PBS-diluted polyclonal ABP
antisera were added and left for 30 min at
room temperature. The
slides were washed three times with PBS, and then
FITC-conjugated
goat antirabbit antibody (diluted 1/200) was added and
left for
30 min at room temperature, followed by additional washing in
PBS. A final rinse in 95% ethanol for 5 min was performed before
mounting. The slides were dried and viewed with a Nikon Microphot-SA
microscope. Photographs were taken with a Nikon 35DX
camera.
 |
RESULTS |
Specific attachment of baculovirus-expressed VP2 virions to CrFK
cells.
In order to identify the cellular receptor from CrFK cells,
it was necessary to obtain large quantities of virions to conduct the
experiments described below. Due to the difficulty in obtaining the
large quantities of purified native ADV virions needed, we used ADV VP2
empty virions (hereafter referred to as VP2 virions) expressed in a
recombinant baculovirus system to experimentally identify the ADV
cellular receptor. Initially we sought to determine if the VP2 virions
attached to cells in a similar fashion as native ADV-G virions. To
address this question, the VP2 virions were radioactively labeled with
125I and assayed for the ability to bind CrFK cells. The
iodinated VP2 virions bound to CrFK cells but did not bind to M
dunni (mouse) cells or SF9 (insect) cells, cell lines that are not
permissive for ADV replication (Fig. 1).
Additionally, the VP2 virion binding to the CrFK cell surface could be
blocked by adding exogenous unlabeled VP2 virions (96% reduction) but
not by adding virions of cowpea chlorotic mottle virus (CCMV), an
unenveloped plant virus similar in size to ADV (Fig. 1). This indicated
that the VP2 virions specifically bound to the surface of CrFK cells.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Binding of baculovirus-expressed VP2 virions to CrFK
cells. 125I-VP2 virions were incubated with CrFK cells and
washed, and cell associated radioactivity was quantitated. VP2 virion
binding to the indicated cells was determined. Competition experiments
examining the ability of iodinated VP2 virions to bind CrFK cells in
the presence of an 18-fold excess of unlabeled VP2 virions or unlabeled
CCMV virions demonstrated that only the VP2 virions could inhibit the
cell binding of radiolabeled VP2 virions. All values are represented as
a percentage of the CrFK-VP2 virion binding. Each experiment was
performed in triplicate, and standard errors are shown.
|
|
The demonstration that the VP2 virions bound to the CrFK cell surface
in a specific manner suggested that they behaved like
native ADV
virions but did not prove that the two types of virions
bound to CrFK
cells by using the same receptor. Competitive binding
experiments
examining the ability of ADV-G virions and VP2 virions
to bind CrFK
cells were conducted to address this concern. CrFK
cells were incubated
with VP2 virions at low temperature, a condition
that allows attachment
but not entry of virions into the cell.
Following preincubation with
VP2 virions, native ADV-G virions
were added and incubated for 1 h. The unbound virus was washed
away, and the cells were incubated for
3 days at an optimal temperature
for ADV replication. The number of
infected cells was determined
by immunofluorescence microscopy with an
antibody to NS1, a nonstructural
protein that is produced only during
active ADV replication. VP2
virions inhibited CrFK infection by ADV-G
by nearly 95%, indicating
that prior binding of VP2 virions to the
CrFK cell surface prevented
ADV-G binding and entry (Fig.
2). In contrast, CCMV virions did
not
inhibit ADV-G infection. Similar results were obtained with
several
preparations of labeled VP2 virions. Taken together, these
results
indicate that VP2 virions bind CrFK cells in a functional
manner
similar to native ADV-G virions.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
Blocking of ADV-G infection of CrFK cells with VP2
virions. VP2 or CCMV virions were preincubated with chilled CrFK cells,
after which ADV-G was added. The cells were then washed and incubated
for 3 days. Infectivity was measured by immunofluorescence microscopy
with ADV NS1 antibody. Each value is represented as a percentage of
that for ADV-G infection of CrFK cells alone, and the standard error is
shown.
|
|
Identification of an ABP by VOPBA analysis.
In order to
identify membrane proteins from CrFK cells that could bind VP2 virions,
we chose to use VOPBA, a biochemical approach proven to be useful in
the identification of several virus receptors (14, 19, 30, 34,
42). The CrFK cell membrane proteins were isolated and used in
the VOPBA to identify proteins that specifically bound radiolabeled VP2
virions. VP2 virions specifically bound a CrFK membrane protein (with
an approximate molecular mass of 67 kDa) that we named ABP (Fig.
3A). No binding of VP2 virions was
observed with membrane proteins from M. dunni cells,
indicating that the binding was cell specific. In addition, labeled
CCMV virions did not bind ABP but interacted nonspecifically with
several other proteins from both CrFK and M. dunni cells.
This indicated that VP2 virion binding by ABP was both cell and virus
specific.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 3.
(A) Identification of a single VP2 virion binding
protein from CrFK cells by VOPBA. One hundred micrograms of either CrFK
or M. dunni membrane proteins was separated on a nonreducing
SDS-8% polyacrylamide gel and processed for VOPBA.
125I-VP2 virions (100,000 cpm/50 µg) were used to probe
the blot on the left, while 125I-CCMV virions (100,000 cpm/55 µg) were used with the blot on the right. (B) Inhibition of
125I-VP2 virion binding to ABP by addition of unlabeled VP2
virions. One hundred micrograms of CrFK membrane proteins was separated
on a nonreducing SDS-8% polyacrylamide gel and processed for VOPBA.
Competing virions were added to the blots just prior to addition of the
125I-VP2 virions (100,000 cpm/50 µg). Left blot,
125I-VP2 virions alone (left lane), addition of an 18-fold
excess (900 µg) of unlabeled VP2 virions (middle lane), and addition
of an 18-fold excess (900 µg) of unlabeled CCMV virions (right lane).
Right blot, 125I-VP2 virions alone (left lane), addition of
an equivalent amount (50 µg) of unlabeled VP2 virions as labeled VP2
virions (middle lane), and addition of a ninefold excess (450 µg) of
unlabeled VP2 virions (right lane). Sizes of molecular weight markers
are in thousands.
|
|
The specificity of the ABP-VP2 virion binding was further analyzed in
competitive binding experiments. Radiolabeled virions
were analyzed for
the ability to bind ABP in the VOPBA when other
unlabeled virions were
present (Fig.
3B). The radiolabeled VP2
virion binding to ABP was
inhibited in a dose-dependent manner
by addition of unlabeled VP2
virions (Fig.
3B). Addition of 18-fold
more unlabeled VP2 virions (900 µg) than radiolabeled VP2 virions
resulted in complete inhibition of
radiolabeled VP2 virion binding
(100% competition). Addition of
an 18-fold excess of unlabeled
CCMV virions was unable to
competitively inhibit radiolabeled
VP2 virion binding, providing
additional evidence that the ABP-VP2
virion binding was a specific
interaction.
A final experiment was conducted to confirm the specificity of the
ABP-VP2 virion interaction. A virion-cell binding assay
was employed to
determine if preincubation of ABP with VP2 virions
could inhibit VP2
virion binding to CrFK cells. Partially purified
ABP was mixed with
radiolabeled VP2 virions for 15 min and tested
for the ability to bind
to CrFK cells. The binding of VP2-ABP
to CrFK cells was reduced by 75%
compared to that of unbound VP2
virions (Fig.
4). This was in comparison to a relative
27% reduction
in CrFK binding observed when VP2 virions were
preincubated with
total CrFK membrane proteins. Incubation of SF9 cell
membrane
proteins with the VP2 virions had no effect on VP2 virion
binding
to CrFK cells. Thus, the binding of ABP to the surface of VP2
virions prevented the virions from attaching to the CrFK cells,
presumably by competition for receptor binding sites on the virion
surface.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 4.
Reduced CrFK binding by VP2 virions when complexed with
ABP. ABP was preincubated with 125I-VP2 virions for 15 min
prior to addition of CrFK cells. The ability of the
125I-virions to bind CrFK cells was then examined. VP2
virions were preincubated either alone or with 500 µg of total CrFK
membrane proteins, 200 µg of partially purified ABP, 500 µg of
total SF9 membrane proteins. Each value is represented as a percentage
of that for VP2 alone, and standard errors from triplicate experiments
are shown.
|
|
Production and characterization of anti-ABP antibodies.
The
previous experiments demonstrated that VP2 virions specifically bound
ABP but did not address the relevance of the binding in the biology of
virus infection. To determine if the interaction between ABP and ADV is
important in virus binding and subsequent entry into the cell, we
raised antibodies against ABP and tested their ability to block ADV
infection of CrFK cells. If native ADV-G attached to CrFK cells through
interactions with ABP, antibody against ABP could potentially interfere
with binding of ADV-G to ABP on the cell surface.
Two polyclonal anti-ABP rabbit antisera specifically reacted with ABP
in a Western blot of CrFK membrane proteins (Fig.
5A).
The antisera reacted with a single
protein migrating at the ABP
molecular mass of 67 kDa. The prebleed
serum control did not show
any such specific reactivity. To ensure that
the antibodies raised
against ABP were specific for only the ABP
protein, 100 µg of
total CrFK membrane proteins was separated by
two-dimensional
gel electrophoresis, Western blotted, and probed with
the ABP
antisera. The results of such analysis are shown for the R2
anti-ABP
serum (Fig.
5B). The R2 ABP antiserum reacted strongly and
specifically
with only one protein having an approximate molecular mass
of
67 kDa. Similar results were found with the R1 ABP antiserum (data
not shown). This analysis also demonstrated that the ABP protein
has a
pI in the range of 7.0 to 8.0. Further analysis will be
required to
accurately determine the exact pI.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 5.
(A) Western blot of CrFK membrane proteins with ABP
polyclonal antisera. Five hundred nanograms of CrFK membrane proteins
was separated by SDS-PAGE, transferred, and incubated with either
normal rabbit serum (prebleed), rabbit R1 anti-ABP polyclonal
antiserum, or rabbit R2 anti-ABP polyclonal antiserum. Each serum was
diluted 1:200. (B) Western blot of CrFK membrane proteins separated by
using a two-dimensional gel where the first dimension was
near-equilibrium pH gel electrophoresis (with ampholines with a pH
range of 3.5 to 9.5) and the second dimension was SDS-PAGE. The blot
was probed with rabbit R2 anti-ABP polyclonal antiserum diluted 1:200.
Sizes of molecular weight markers are in thousands.
|
|
One of the anti-ABP antisera, the R2 anti-ABP antiserum, was chosen to
test the ability of the sera to bind ABP on the surface
of CrFK
cells. Immunofluorescence microscopy of CrFK cells incubated
with
the R2 anti-ABP antibodies showed selective staining of the
CrFK cell
surfaces, whereas that with the prebleed serum did not
(Fig.
6A). The anti-ABP sera did not react with
either
M. dunni or SF9 cells (data not shown). ADV-G
infection of CrFK cells was
blocked when the cells were preincubated
with these antibodies
(Fig.
6B). Both of the anti-ABP polyclonal
antisera tested blocked
ADV-G infection of CrFK cells (73 and 67%
blocking, respectively),
with an optimal dilution of 1:10. The prebleed
serum had no effect
on ADV-G infectivity. The blocking of ADV-G
infection indicated
that ADV binding to ABP was required for binding
and entry into
the cell to establish infection.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 6.
(A) Immunofluorescence microscopy of CrFK cells with
rabbit R2 anti-ABP polyclonal antiserum. CrFK cells, fixed with
formaldehyde, were stained with with a 1:10 dilution of either rabbit
prebleed serum or rabbit R2 anti-ABP polyclonal antiserum. An
FITC-conjugated goat antirabbit polyclonal antibody was used as the
secondary stain. The two fields contained similar numbers of cells. The
photograph for the prebleed serum was taken with an exposure four times
longer than that for the R2 anti-ABP serum. (B) Blocking of ADV-G
infection in CrFK cells with anti-ABP polyclonal antisera. Rabbit sera,
diluted 1:10 in medium, were preincubated with CrFK cells for 30 min at
4°C. ADV-G was added at an MOI of 1 and incubated for 30 min. The
cells were washed and incubated for 3 days, after which they were
analyzed by immunofluorescence microscopy with ADV NS1 antibody. NRS,
normal rabbit prebleed serum. The results are graphed as relative
percentages of that for the ADV-G-normal rabbit serum experiment, and
standard errors are shown.
|
|
 |
DISCUSSION |
In this study we have identified a putative cellular receptor for
ADV, a single protein with a molecular mass of 67 kDa that specifically
binds ADV VP2 virions. This protein, which we have named ABP, has many
characteristics expected of a cellular receptor: (i) ABP is expressed
on the surface of CrFK cells and specifically binds VP2 virions, (ii)
ABP binding of VP2 virions prevents virion binding to CrFK cells, (iii)
VP2 virion binding to ABP on the CrFK cell surface prevents native
ADV-G virions from infecting the cells, and (iv) antibodies directed
against ABP bind to ABP on the CrFK cell surface and block infection by
ADV-G.
In our identification of ABP, we used baculovirus-expressed VP2
virions. Although such artificially expressed virions potentially differ from native ADV virions in terms of cell binding and entry, we
addressed this concern by demonstrating that VP2 virions compete with
native ADV-G virions for cell binding. The baculovirus-expressed VP2
empty virions are morphologically and antigenically indistinguishable from ADV-G (8a). For other parvovirus systems, determination of the atomic structures of the native virions and empty VP2 empty virions has shown very few differences between the two virion types
(1). In addition, it was demonstrated that the
baculovirus-expressed B19 VP2 virions are antigenically and
immunologically similar to the native virions (26). Thus,
there is no reason to believe that the ADV VP2 empty virions behave
differently from ADV-G in cell binding.
By using immunofluorescence microscopy, antibodies raised against ABP
were reacted specifically with the surfaces of live and fixed CrFK
cells. The ABP antisera, when preincubated with CrFK cells, blocked
infection of the cells by ADV-G. The simplest explanation for this
result is that the antibodies bind ABP and in doing so prevent ADV-G
virions from binding to the cell surface. Precedence for this exists in
a number of virus systems. Antibodies raised against two
VOPBA-identified surface proteins from C6/36 cells specifically blocked
dengue virus type 4 infection (42). In addition, antibodies
raised against biochemically identified cell surface proteins from
echovirus, Norwalk virus, Venezuelan equine encephalitis virus,
papillomavirus, and porcine reproductive respiratory syndrome virus
systems have been shown to specifically block attachment to and thus
infection of susceptible cells (21, 23, 30, 32, 48). The
possibility does exist that anti-ABP antibodies are nonspecifically
blocking ADV-G attachment by steric hindrance to another,
yet-unidentified, protein that is the real receptor for ADV. However,
the additional data showing specific binding of ADV to ABP argues
against this interpretation. Complete blocking of ADV-G infection was
not obtained. Reductions of 73 and 67% were observed with the two
antisera. This is most likely due to the technical inability to block
every single ABP molecule on every cell. A single unbound ABP molecule
could result in virus binding, and the cell would score positive for
infection in our assay.
Experiments demonstrating the blocking of CrFK cell binding by
ABP-complexed VP2 virions further support the hypothesis that ABP is
the ADV cellular receptor. This, along with the antibody evidence
discussed above, suggests that ABP is necessary for ADV binding to CrFK
cells. The partially purified ABP used in the blocking experiments
still contains other proteins (the ABP preparation was estimated to be
approximately 70% pure) which could be playing a role in binding
inhibition. However, the significant difference seen in binding
inhibition between total CrFK membrane proteins and partially purified
ABP suggests that ABP is the cause of the dramatic decrease in virion
binding. We did not observe a significant increase in concentration of
any other proteins in the partially purified ABP that could contribute
to the dramatic decrease in virus binding observed. Experiments to
purify ABP to homogeneity for more detailed analyses are under way.
During optimization of the VOPBA, we found that the inclusion of
detergents in VOPBA buffers decreased the specificity of binding to
CrFK membrane proteins by VP2 virions. Omitting detergents from the
buffers resulted in the specific binding of ABP by VP2 virions. One
reason that the detergents may promote nonspecific binding is that the
detergents are interacting with hydrophobic, transmembrane regions of
the membrane proteins on the VOPBA blot. The virions may be
nonspecifically interacting with the membrane protein-associated
detergents. Work by Alexandersen et al. demonstrated that ADV has a
propensity to interact with hydrophobic cell membrane components due to
the amphiphilic nature of the virion exterior (4). Thus,
when detergents are present, the VP2 virions are likely interacting
with the immobilized protein-detergent complexes in a nonspecific manner.
Previous work by two different laboratories with another parvovirus,
CPV, attempted to use a similar approach in identifying its cellular
receptor (6, 46). Both of those reports identified multiple proteins that bound CPV. The proteins identified were different in each report, most likely because the cell lines used differed. The report by Barbis et al. (6) demonstrated that binding of some of the proteins from rhesus monkey erythrocytes, required for hemagglutination, was dependent on protein-associated sialic acid moieties, while others were not. While both ADV and CPV are
parvoviruses, the differ greatly and are only distantly related among
the parvoviruses. ADV has approximately 40 more amino acid residues in
VP2 than does CPV. A significant proportion of these amino acid
residues are positioned in the loop 3-4 region of VP2, a region of the
protein that is positioned on the virion surface at, or near, the
virion threefold axis of symmetry (33). This region is
hypothesized to be important for receptor binding and has been
demonstrated to contain amino acid residues that affect host range in
the CPV and feline panleukopenia virus systems as well as in ADV
(23a, 40, 45).
Native ADV virions contain 60 protein molecules of which about 10% are
VP1. The VP1 protein contains all of the amino acids encoded by the
VP2-coding region with approximately 40 additional amino acid residues
on the N terminus. Our results indicate that the receptor binding
component of ADV virions is contained within the VP2-coding region,
since the baculovirus-expressed VP2 empty virions do not contain
VP1. VP1 empty virions can be expressed in baculovirus and contain
approximately 90% VP1 and 10% VP2 (the opposite of what is found in
native virions). The VP1 virions were analyzed for their ability to
bind ABP in the VOPBA and were found to behave similarly to VP2 virions
(data not shown). These results indicate that the VP1 unique region
does not significantly influence receptor binding.
The identification of the ADV receptor utilized in permissive infection
will undoubtedly contribute to future studies aimed at understanding
the biology of ADV pathogenesis. An important but unanswered question
in ADV pathogenesis is which cells in the mink are capable of being
infected. Experiments identifying infected cells have been limited by
the sensitivity of assays detecting virus replication. Using the
antibodies to ABP, we plan to screen various mink cell populations for
the cell surface expression of an ABP homologue. If these antibodies
are capable of cross-reacting with the mink equivalent of ABP, we will
be able to identify which cell populations can potentially be infected.
In addition, defining the ADV-receptor complex in chemical terms will
offer the possibility of designing therapies that could potentially
interfere with this interaction and block virus infection. This would
be highly desirable for the treatment of mink kits that have contracted
ADV, because the mortality rate is often high and there is not
currently a method to either prevent or cure the infection in such kits.
 |
ACKNOWLEDGMENTS |
We thank Klaus Jensen, Mavis Agbandge-McKenna, and Mary Ann
Stevenson for helpful discussions. We also thank Kim Hasenkrug, John
Portis, and Sue Priola for critical reading of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: 903 S. 4th St.,
Hamilton, MT 59840. Phone: (406) 363-9284. Fax: (406) 363-9286. E-mail: jfox{at}atlas.niaid.nih.gov.
 |
REFERENCES |
| 1.
|
Agbandje, M.,
C. R. Parrish, and M. G. Rossmann.
1995.
The structure of parvoviruses.
Semin. Virol.
6:299-309.
|
| 2.
|
Alexandersen, S.,
M. E. Bloom, and S. Perryman.
1988.
Detailed transcription map of Aleutian mink disease parvovirus.
J. Virol.
62:3684-3694[Abstract/Free Full Text].
|
| 3.
|
Alexandersen, S.,
M. E. Bloom, and J. Wolfinbarger.
1988.
Evidence of restricted viral replication in adult mink infected with Aleutian disease of mink parvovirus.
J. Virol.
62:1495-1507[Abstract/Free Full Text].
|
| 4.
|
Alexandersen, S.,
J. Hau, and S. Larsen.
1984.
Examination of Aleutian disease virus in charge-shift crossed immunoelectrophoresis.
Acta Pathol. Microbiol. Immunol. Scand. Sect. B
92:331-334[Medline].
|
| 5.
|
Alexandersen, S.,
A. Uttenthal-Jensen,
M. Hansen, and B. Aasted.
1985.
Experimental transmission of Aleutian disease virus (ADV) to different animal species.
Acta Pathol. Microbiol. Immunol. Scand. Sect. B
93:195-200[Medline].
|
| 6.
|
Barbis, D. P.,
S.-F. Chang, and C. R. Parrish.
1992.
Mutations adjacent to the dimple of the canine parvovirus capsid structure affect sialic acid binding.
Virology
191:301-308[Medline].
|
| 7.
|
Barbis, D. P., and C. R. Parrish.
1994.
Characterization of canine parvovirus (CPV) interactions with 3201 T cells: involvement of GPI-anchored protein(s) in binding and infection.
Braz. J. Med. Biol. Res.
27:401-407[Medline].
|
| 8.
|
Bass, D. M., and H. B. Greenberg.
1992.
Strategies for the identification of icosahedral virus receptors.
J. Clin. Invest.
89:3-9.
|
| 8a.
| Bloom, M. E. Unpublished data.
|
| 9.
|
Bloom, M. E.,
S. Alexandersen,
S. Mori, and J. B. Wolfinbarger.
1989.
Analysis of parvovirus infections using strand-specific hybridization probes.
Virus Res.
14:1-26[Medline].
|
| 10.
|
Bloom, M. E.,
S. Alexandersen,
S. Perryman,
D. Lechner, and J. B. Wolfinbarger.
1988.
Nucleotide sequence and genomic organization of Aleutian mink disease parvovirus (ADV): sequence comparisons between a nonpathogenic and a pathogenic strain of ADV.
J. Virol.
62:2903-2915[Abstract/Free Full Text].
|
| 11.
|
Bloom, M. E.,
B. D. Berry,
W. Wei,
S. Perryman, and J. B. Wolfinbarger.
1993.
Characterization of chimeric full-length molecular clones of Aleutian mink disease parvovirus (ADV): identification of a determinant governing replication of ADV in cell culture.
J. Virol.
67:5976-5988[Abstract/Free Full Text].
|
| 12.
|
Bloom, M. E.,
H. Kanno,
S. Mori, and J. B. Wolfinbarger.
1994.
Aleutian mink disease: puzzles and paradigms.
Infect. Agents Dis.
3:279-301[Medline].
|
| 13.
|
Bloom, M. E.,
R. E. Race, and J. B. Wolfinbarger.
1980.
Characterization of Aleutian disease virus as a parvovirus.
J. Virol.
35:836-843[Abstract/Free Full Text].
|
| 14.
|
Borrow, P., and M. B. Oldstone.
1992.
Characterization of lymphocytic choriomeningitis virus-binding protein(s): a candidate cellular receptor for the virus.
J. Virol.
66:7270-7281[Abstract/Free Full Text].
|
| 15.
|
Brown, K. E.,
S. M. Anderson, and N. S. Young.
1993.
Erythrocyte P antigen: cellular receptor for B19 parvovirus.
Science
262:114-117[Abstract/Free Full Text].
|
| 16.
|
Christensen, J.,
S. Alexandersen,
B. Bloch,
B. Aasted, and A. Uttenthal.
1994.
Production of mink enteritis parvovirus empty capsids by expression in a baculovirus vector system: a recombinant vaccine for mink enteritis parvovirus in mink.
J. Gen. Virol.
75:149-155[Abstract/Free Full Text].
|
| 17.
|
Christensen, J.,
T. Storgaard,
B. Bloch,
S. Alexandersen, and B. Aasted.
1993.
Expression of Aleutian mink disease parvovirus proteins in a baculovirus vector system.
J. Virol.
67:229-238[Abstract/Free Full Text].
|
| 18.
|
Cotmore, S. F., and P. Tattersall.
1989.
A genome-linked copy of the NS-1 polypeptide is located on the outside of infectious parvovirus particles.
J. Virol.
63:3902-3911[Abstract/Free Full Text].
|
| 19.
|
de Verdugu, V. R.,
H. C. Selinka,
M. Huber,
B. Kramer,
J. Kellermann,
P. H. Hofschneider, and R. Kandolf.
1995.
Characterization of a 100-kilodalton binding protein for the six serotypes of coxsackie B viruses.
J. Virol.
69:6751-6757[Abstract].
|
| 20.
|
Dimmock, N. J.
1982.
Initial stages in infection with animal viruses.
J. Gen. Virol.
59:1-22[Abstract/Free Full Text].
|
| 21.
|
Duan, X.,
H. J. Nauwynck,
H. W. Favoreel, and M. B. Pensaert.
1998.
Identification of a putative receptor for porcine reproductive and respiratory syndrome virus on porcine alveolar macrophages.
J. Virol.
72:4520-4523[Abstract/Free Full Text].
|
| 22.
|
Dworak, L. J.,
J. B. Wolfinbarger, and M. E. Bloom.
1997.
Aleutian mink disease parvovirus infection of K562 cells is antibody-dependent and is mediated via an Fc(gamma)RII receptor.
Arch. Virol.
142:363-373[Medline].
|
| 23.
|
Evander, M.,
I. H. Frazer,
E. Payne,
Y. M. Qi,
K. Hengst, and N. A. McMillan.
1997.
Identification of the alpha6 integrin as a candidate receptor for papillomaviruses.
J. Virol.
71:2449-2456[Abstract].
|
| 23a.
| Fox, J. M., and M. E. Bloom. Unpublished
data.
|
| 24.
|
Gorham, J. R.,
J. B. Henson,
T. B. Crawford, and G. A. Padgett.
1976.
The epizootiology of Aleutian disease, p. 135-158.
In
R. H. Kimberlin (ed.), Slow virus diseases of animals and man. North-Holland Publishing Co., Amsterdam, The Netherlands.
|
| 25.
|
Goto, H.
1975.
Feline panleukopenia in Japan. II. Hemagglutinability of the isolated virus.
Nippon. Juigaku. Zasshi.
37:239-245[Medline].
|
| 26.
|
Kajigaya, S.,
A. Fujii,
A. M. Field,
S. Anderson,
T. Shimada, and N. S. Young.
1991.
B19 parvovirus capsids produced in a baculovirus system are antigenically and immunologically similar to native virions.
Proc. Natl. Acad. Sci. USA
88:4646-4650[Abstract/Free Full Text].
|
| 27.
|
Kenyon, A. J.,
B. J. Kenyon, and E. C. Hahn.
1978.
Protides of the Mustelidae: immunoresponse of mustelids to Aleutian mink disease virus.
Am. J. Vet. Res.
39:1011-1015[Medline].
|
| 28.
|
Krilov, L. R.,
L. J. Anderson,
L. Marcoux,
V. R. Bonagura, and J. F. Wedgwood.
1989.
Antibody-mediated enhancement of respiratory syncytial virus infection in two monocyte/macrophage cell lines.
J. Infect. Dis.
160:777-782[Medline].
|
| 29.
|
Linser, P.,
H. Bruning, and R. W. Armentrout.
1977.
Specific binding sites for a parvovirus, minute virus of mice, on cultured mouse cells.
J. Virol.
24:211-221[Abstract/Free Full Text].
|
| 30.
|
Ludwig, G. V.,
J. P. Kondig, and J. F. Smith.
1996.
A putative receptor for Venezuelan equine encephalitis virus from mosquito cells.
J. Virol.
70:5592-5599[Abstract/Free Full Text].
|
| 31.
|
Mady, B. J.,
D. V. Erbe,
I. Kurane,
M. W. FAnger, and F. A. Ennis.
1991.
Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against surface molecules other than Fcgamma receptors.
J. Immunol.
147:3139-3144[Abstract].
|
| 32.
|
Mbida, A. D.,
B. Pozzetto,
O. G. Gaudin,
F. Grattard,
B. J. Le,
Y. Akono, and A. Ros.
1992.
A 44,000 glycoprotein is involved in the attachment of echovirus-11 onto susceptible cells.
Virology
189:350-353[Medline].
|
| 33.
| McKenna, R., N. H. Olson, P. R. Chipman,
T. S. Baker, T. F. Booth, J. Christensen, B. Aasted,
J. M. Fox, M. E. Bloom, and M. Agbandje-McKenna. The
three-dimensional structure of Aleutian mink disease parvovirus:
implications for disease pathogenicity. Submitted for publication.
|
| 34.
|
Mizukami, H.,
N. S. Young, and K. E. Brown.
1996.
Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein.
Virology
217:124-130[Medline].
|
| 35.
|
Mochizuki, M.,
S. Konishi, and M. Ogata.
1978.
Studies on feline panleukopenia. II. Antigenicities of the virus.
Nippon. Juigaku. Zasshi.
40:375-383[Medline].
|
| 36.
|
Mori, S.,
J. B. Wolfinbarger,
N. Dowling,
W. Wei, and M. E. Bloom.
1991.
Simultaneous identification of viral proteins and nucleic acids in cells infected with Aleutian mink disease parvovirus.
Microb. Pathog.
9:243-253.
|
| 37.
|
Mori, S.,
J. B. Wolfinbarger,
M. Miyazawa, and M. E. Bloom.
1991.
Replication of Aleutian mink disease parvovirus in lymphoid tissues of adult mink: involvement of follicular dendritic cells and macrophages.
J. Virol.
65:952-956[Abstract/Free Full Text].
|
| 38.
|
Norkin, L. C.
1995.
Virus receptors: implications for pathogenesis and the design of antiviral agents.
Clin. Microbiol. Rev.
8:293-315[Abstract].
|
| 39.
|
Oleksiewicz, M. B.,
F. Costello,
M. Huhtanen,
J. B. Wolfinbarger,
S. Alexandersen, and M. E. Bloom.
1996.
Subcellular localization of Aleutian mink disease parvovirus proteins and DNA during permissive infection of Crandell feline kidney cells.
J. Virol.
70:3242-3247[Abstract].
|
| 40.
|
Parker, J. S. L., and C. R. Parrish.
1998.
Canine parvovirus host range is determined by the specific conformation of an additional region of the capsid.
J. Virol.
71:9214-9222[Abstract].
|
| 41.
|
Porter, D. D.,
A. E. Larsen,
N. A. Cook,
H. G. Porter, and S. L. Suffin.
1977.
Isolation of Aleutian disease virus of mink in cell culture.
Intervirology
8:129-144[Medline].
|
| 42.
|
Salas-Benito, J. S., and R. M. del Angel.
1997.
Identification of two surface proteins from C6/C36 cells that bind dengue type 4 virus.
J. Virol.
71:7246-7252[Abstract].
|
| 43.
|
Saliki, J. T.,
B. Mizak,
H. P. Flore,
R. R. Gettig,
J. P. Burand,
L. E. Carmichael,
H. A. Wood, and C. R. Parrish.
1992.
Canine parvovirus empty capsids produced by expression in a baculovirus vector: use in analysis of viral properties and immunization of dogs.
J. Gen. Virol.
73:369-374[Abstract/Free Full Text].
|
| 44.
|
Summerford, C., and R. J. Samulski.
1998.
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.
J. Virol.
72:1438-1445[Abstract/Free Full Text].
|
| 45.
|
Truyen, U., and C. R. Parrish.
1992.
Canine and feline host ranges of canine parvovirus and feline panleukopenia virus: distinct host cell tropisms of each virus in vitro and in vivo.
J. Virol.
66:5399-5408[Abstract/Free Full Text].
|
| 46.
|
Uwatoko, K.,
R. Kano,
M. Sunairi,
M. Nakajima, and K. Yamaura.
1996.
Canine parvovirus binds to multiple cellular membrane proteins from both permissive and nonpermissive cell lines.
Vet. Microbiol.
51:267-273[Medline].
|
| 47.
|
Weir, D. M.
1989.
Carbohydrates as recognition molecules in infection and immunity.
FEMS Microbiol. Immunol.
1:331-340[Medline].
|
| 48.
|
White, L. J.,
J. M. Ball,
M. E. Hardy,
T. N. Tanaka,
N. Kitamoto, and M. K. Estes.
1996.
Attachment and entry of recombinant Norwalk virus capsids to cultured human and animal cell lines.
J. Virol.
70:6589-6597[Abstract/Free Full Text].
|
| 49.
|
Wu, W.-H.,
M. E. Bloom,
B. D. Berry,
M. J. McGinley, and K. B. Platt.
1994.
Expression of Aleutian mink disease parvovirus capsid proteins in a baculovirus expression system for potential diagnostic use.
J. Vet. Diagn. Invest.
6:23-29[Abstract/Free Full Text].
|
Journal of Virology, May 1999, p. 3835-3842, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lopez-Bueno, A., Rubio, M.-P., Bryant, N., McKenna, R., Agbandje-McKenna, M., Almendral, J. M.
(2006). Host-Selected Amino Acid Changes at the Sialic Acid Binding Pocket of the Parvovirus Capsid Modulate Cell Binding Affinity and Determine Virulence. J. Virol.
80: 1563-1573
[Abstract]
[Full Text]
-
Johnson, F. B., Fenn, L. B., Owens, T. J., Faucheux, L. J., Blackburn, S. D.
(2004). Attachment of bovine parvovirus to sialic acids on bovine cell membranes. J. Gen. Virol.
85: 2199-2207
[Abstract]
[Full Text]
-
Bose, S., Basu, M., Banerjee, A. K.
(2004). Role of Nucleolin in Human Parainfluenza Virus Type 3 Infection of Human Lung Epithelial Cells. J. Virol.
78: 8146-8158
[Abstract]
[Full Text]
-
Best, S. M., Shelton, J. F., Pompey, J. M., Wolfinbarger, J. B., Bloom, M. E.
(2003). Caspase Cleavage of the Nonstructural Protein NS1 Mediates Replication of Aleutian Mink Disease Parvovirus. J. Virol.
77: 5305-5312
[Abstract]
[Full Text]
-
Rubio, M.-P., Guerra, S., Almendral, J. M.
(2001). Genome Replication and Postencapsidation Functions Mapping to the Nonstructural Gene Restrict the Host Range of a Murine Parvovirus in Human Cells. J. Virol.
75: 11573-11582
[Abstract]
[Full Text]
-
Bloom, M. E., Best, S. M., Hayes, S. F., Wells, R. D., Wolfinbarger, J. B., McKenna, R., Agbandje-McKenna, M.
(2001). Identification of Aleutian Mink Disease Parvovirus Capsid Sequences Mediating Antibody-Dependent Enhancement of Infection, Virus Neutralization, and Immune Complex Formation. J. Virol.
75: 11116-11127
[Abstract]
[Full Text]
-
Parker, J. S. L., Parrish, C. R.
(2000). Cellular Uptake and Infection by Canine Parvovirus Involves Rapid Dynamin-Regulated Clathrin-Mediated Endocytosis, Followed by Slower Intracellular Trafficking. J. Virol.
74: 1919-1930
[Abstract]
[Full Text]
-
McKenna, R., Olson, N. H., Chipman, P. R., Baker, T. S., Booth, T. F., Christensen, J., Aasted, B., Fox, J. M., Bloom, M. E., Wolfinbarger, J. B., Agbandje-McKenna, M.
(1999). Three-Dimensional Structure of Aleutian Mink Disease Parvovirus: Implications for Disease Pathogenicity. J. Virol.
73: 6882-6891
[Abstract]
[Full Text]